Latest net tangible assets for XENE: $1.2B.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Xenon Pharmaceuticals (XENE) currently reports a net tangible assets of $1.2B as of June 2026. That compares with $630M in the prior-year period — up 96.0% year over year. Use the charts on this page to explore Xenon Pharmaceuticals's net tangible assets history and peer comparisons.
Xenon Pharmaceuticals's net tangible assets increased from $630M to $1.2B — a 96.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Xenon Pharmaceuticals reported $1.2B in net tangible assets as of June 2026. That compares with $630M in the prior-year period — up 96.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current net tangible assets of $1.2B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Xenon Pharmaceuticals, and consider following XENE for alerts when major investors trade the stock.
Xenon Pharmaceuticals is classified in the Healthcare sector. On net tangible assets, it currently shows $1.2B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XENE with unrelated industries.